SCHEMBL2817995

SCHEMBL2817995

COc1ccc(C(=O)O)c(Cl)c1OC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.66
MAPT P10636 1/20 0.66
ALDH1A1 P00352 4/20 0.47
CLCN2 P51788 1/20 0.47
KDM4E B2RXH2 3/20 0.46
HSD17B10 Q99714 1/20 0.46
PDE4D Q08499 3/20 0.46
CDC25B P30305 1/20 0.45
HPGD P15428 2/20 0.43
HTT P42858 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA7 P43166 1/20 0.43
TPMT P51580 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18529850 0.86 TDP1 (0.52) TDP1MAPTALDH1A1CLCN2KDM4E
SCHEMBL31346670 0.85 MAPT (0.51) TDP1MAPTALDH1A1KDM4EHSD17B10
SCHEMBL7032033 0.85 MAPT (0.51) TDP1MAPTPDE4DPOLBMAPK1
SCHEMBL6931814 0.85 TDP1 (0.55) TDP1MAPTALDH1A1CLCN2KDM4E
SCHEMBL30949565 0.85 TDP1 (0.55) TDP1MAPTALDH1A1CLCN2KDM4E
SCHEMBL10407306 0.84 TDP1 (0.50) TDP1MAPTKDM4EPDE4DHTT
SCHEMBL17063591 0.83 ALDH1A1 (0.61) TDP1MAPTALDH1A1CLCN2KDM4E
SCHEMBL7693236 0.82 TDP1 (0.50) TDP1MAPTALDH1A1CLCN2KDM4E
SCHEMBL102827 0.82 MAPT (0.72) TDP1MAPTALDH1A1KDM4EPDE4D
SCHEMBL27978300 0.82 MAPT (0.60) TDP1MAPTALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092083-A1 VANCOMYCIN DERIVATIVES WITH SIDEROPHORE MODIFICATION AS NOVEL REPURPOSED ANTIBIOTICS TO COMBAT GRAM-NEGATIVE BACTERIAL INFECTION RESEARCH TRIANGLE INSTITUTE (US) 2026-04-02 US disclosed
EP-4676533-A1 VANCOMYCIN DERIVATIVES WITH SIDEROPHORE MODIFICATION AS NOVEL REPURPOSED ANTIBIOTICS TO COMBAT GRAM-NEGATIVE BACTERIAL INFECTION Research Triangle Institute (US) 2026-01-14 EP disclosed
EP-4652154-A1 NOVEL ALPK1 INHIBITORS Pyrotech (Beijing) Biotechnology Co., Ltd. (CN) 2025-11-26 EP disclosed
WO-2025202864-A1 ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER iTeos Belgium SA (BE) 2025-10-02 WO disclosed
WO-2025124531-A1 1, 3-BENZODIOXOL DERIVATIVES AND USES THEREOF GEWU BIO CO., LTD (CN) 2025-06-19 WO disclosed
WO-2025104613-A1 ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS iTeos Belgium SA (BE) 2025-05-22 WO disclosed
CN-119390668-A Compound with ketoxime ether structure and application thereof 复旦大学 2025-02-07 CN disclosed
CN-115867535-B Substituted benzamides as modulators of TREX1 星座制药公司 2024-12-17 CN disclosed
WO-2024191690-A1 VANCOMYCIN DERIVATIVES WITH SIDEROPHORE MODIFICATION AS NOVEL REPURPOSED ANTIBIOTICS TO COMBAT GRAM-NEGATIVE BACTERIAL INFECTION RESEARCH TRIANGLE INSTITUTE (US) 2024-09-19 WO disclosed
EP-3997096-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2024-08-28 EP disclosed
EP-1368354-A1 MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Pfizer Products Inc. (US) 2003-12-10 EP disclosed
EP-1093367-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-03-05 EP disclosed
US-6509366-B2 Substituted imidazoles as selective modulators of Bradykinin B2 receptors NEUROGEN CORPORATION 2003-01-21 US disclosed
US-20030008893-A1 Modulators of chemokine receptor activity COLON-CRUZ ROBERTO (US) 2003-01-09 US disclosed
WO-2002070523-A1 MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY PFIZER PRODUCTS INC. (US) 2002-09-12 WO disclosed
US-20020115693-A1 Substituted imidazoles as selective modulators of bradykinin B2 receptors NEUROGEN CORPORATION 2002-08-22 US disclosed
WO-2001056995-A1 SUBSTITUTED IMIDAZOLES AS SELECTIVE MODULATORS OF BRADYKININ B2 RECEPTORS NUEROGEN CORPORATION (US) 2001-08-09 WO disclosed
EP-1093367-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-04-25 EP disclosed
WO-1999066925-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-12-29 WO disclosed
US-5332735-A Antiamnesic activity ADIR ET COMPAGNIE (FR) 1994-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092083-A1 VANCOMYCIN DERIVATIVES WITH SIDEROPHORE MODIFICATION AS NOVEL REPURPOSED ANTIBIOTICS TO COMBAT GRAM-NEGATIVE BACTERIAL INFECTION SLC11A2, SLC39A11, SLC39A3 TDP1 4752/4885MAPT 4839/4885ALDH1A1 2826/4885
US-20030008893-A1 Modulators of chemokine receptor activity CCR1, CCR3, CCR2 TDP1 3700/4885MAPT 4154/4885ALDH1A1 1764/4885
US-20020115693-A1 Substituted imidazoles as selective modulators of bradykinin B2 receptors BDKRB2, BDKRB1, KISS1R TDP1 3822/4885MAPT 3044/4885ALDH1A1 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.